Sofinnova Partners led a $157m Series C round in Hemab.

Sofinnova Partners, a French venture capital firm, led a $157m Series C round in Hemab, a multiple clinical-asset biotechnology company, with participation from RA Capital Management, Novo Holdings, Access Biotechnology, Deep Track Capital, HealthCap, Invus, Avoro, Maj Invest Equity, and Rock Springs Capital. The additional capital enables Hemab to advance additional novel drug candidates into clinical development, with HMB-003 expected to be announced in H1 2026. This expanded pipeline reinforces Hemab's commitment to developing comprehensive treatment solutions across the spectrum of high unmet need bleeding disorders.